A second-generation VDA focused on hematologic malignancies; initiated Phase 1b/2 trials in 2015. Myopic Macular Degeneration
OXiGENE’s primary development programs were based on , natural products originally derived from the African bush willow tree. Drug Candidate Indication Current Status/Highlights CA4P (Fosbretabulin) Ovarian Cancer, Glioblastoma, Anaplastic Thyroid Cancer Oxigene
On June 20, 2016, OXiGENE officially became Mateon Therapeutics (formerly NASDAQ: OXGN, now MATN). Despite promising science
Despite promising science, the company faced periodic financial restructurings, including a significant workforce reduction in 2011 to conserve resources for early-stage programs. the company faced periodic financial restructurings
The shift to Mateon Therapeutics reflected a broader focus on "Vascular Targeted Therapy" (VTT), which combines VDAs with anti-angiogenic agents to trap and destroy tumor cores while preventing new vessel growth. Historical Acquisitions:
Investigated as a topical or systemic treatment to prevent abnormal blood vessel leakage in the eye.